End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 MYR | +0.72% | +6.46% | +3.70% |
Mar. 12 | Malaysian Stocks Maintain Four-Day Winning Streak; Kobay Technology's Shares Rally 12% | MT |
Feb. 07 | Hartalega Sets Up Share Grant Scheme | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 156.77 and 47.52 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.02 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.70% | 2B | B | ||
+8.39% | 27.27B | B+ | ||
-29.83% | 3.12B | B- | ||
-15.97% | 2.53B | C+ | ||
+18.11% | 2.47B | - | A- | |
-9.47% | 1.91B | - | ||
-2.22% | 1.48B | B | ||
+2.78% | 1.3B | - | ||
+18.92% | 1.18B | C | ||
+3.72% | 1.13B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HARTA Stock
- Ratings Hartalega Holdings